Vitalant: Single Audit Reports and Findings
Vitalant filed 9 single audits between 2016 and 2024; the most recently observed auditor is ERNST & YOUNG LLP (2024), and the 2024 report lists 0 findings. Data as of 2026-09-18.
Data as of Sep 18, 2026 · Source: Federal Audit Clearinghouse (public data)
Single audits by year
One row per audit year as the Federal Audit Clearinghouse accepted it. The auditor named is the one observed on that filing; Vitalant is recorded in SCOTTSDALE, Arizona under EIN 860098929, and the Clearinghouse records it as a nonprofit.
| Audit year | Fiscal year end | Federal expended | Threshold applied | Auditor observed | Findings | MW / SD | FAC report |
|---|---|---|---|---|---|---|---|
| 2024 | 2024-12-31 | $15,277,595 | $750,000 | ERNST & YOUNG LLP | 0 | — | 2024-12-GSAFAC-0000382445 |
| 2023 | 2023-12-31 | $17,442,389 | $750,000 | ERNST & YOUNG LLP | 0 | — | 2023-12-GSAFAC-0000057288 |
| 2022 | 2022-12-31 | $17,795,762 | $750,000 | ERNST & YOUNG LLP | 0 | — | 2022-12-CENSUS-0000111519 |
| 2021 | 2021-12-31 | $44,546,816 | $1,336,404 | ERNST & YOUNG LLP | 0 | — | 2021-12-CENSUS-0000111519 |
| 2020 | 2020-12-31 | $13,288,168 | $750,000 | ERNST & YOUNG LLP | 0 | — | 2020-12-CENSUS-0000111519 |
| 2019 | 2019-12-31 | $10,606,130 | $750,000 | GRANT THORNTON LLP | 0 | — | 2019-12-CENSUS-0000111519 |
| 2018 | 2018-12-31 | $10,025,666 | $750,000 | GRANT THORNTON LLP | 0 | — | 2018-12-CENSUS-0000111519 |
| 2017 | 2017-12-31 | $10,589,788 | $750,000 | GRANT THORNTON LLP | 5 | SD | 2017-12-CENSUS-0000111519 |
| 2016 | 2016-12-31 | $9,151,346 | $750,000 | GRANT THORNTON LLP | 0 | — | 2016-12-CENSUS-0000111519 |
Which federal programs did this organization report?
From the most recent accepted report. "Major" is the designation the auditor made under 2 CFR 200.518, not ours.
| ALN | Program | Expended | Major |
|---|---|---|---|
| 93.RD | RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY IV - PEDIATRIC (REDS-IV-P) - CENTER FOR TRANSFUSION LABORATORY STUDIES (CTLS) | $3,298,027 | Yes |
| 93.RD | COVID-19 - NATIONAL SARS-COV-2 SEROINCIDENCE STUDIES IN BLOOD DONORS | $2,385,363 | Yes |
| 93.RD | TRANSFUSION-TRANSMISSIBLE INFECTIONS MONITORING SYSTEM (TTIMS) LABORATORY AND RISK FACTOR COORDINATING CENTER (LRCC) | $1,988,645 | Yes |
| 93.RD | RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY IV - PEDIATRIC (REDS-IV-P) BRAZIL TRANSFUSION SAFETY RESEARCH PROGRAM | $1,425,065 | Yes |
| 93.RD | RECIPIENT EPIDEMIOLOGY AND DONOR EVALUATION STUDY IV - PEDIATRIC (REDS-IV-P) - DOMESTIC HUB | $1,269,157 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $740,623 | Yes |
| 93.RD | NIAID VIROLOGY QUALITY ASSURANCE (VQA) | $496,169 | Yes |
| 93.839 | BLOOD DISEASES AND RESOURCES RESEARCH | $467,682 | Yes |
| 93.839 | BLOOD DISEASES AND RESOURCES RESEARCH | $435,450 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $384,796 | Yes |
| 93.839 | BLOOD DISEASES AND RESOURCES RESEARCH | $325,717 | Yes |
| 93.RD | EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY (EQAPOL) | $257,998 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $230,818 | Yes |
| 93.RD | NIAID EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY (EQAPOL) | $228,532 | Yes |
| 93.RD | DEVELOPMENT, VALIDATION & USE OF BIOTINYLATION TO MEASURE POST-TRANSFUSION RED BLOOD CELL KINETRICS IN THE CONTEXT OF REGULATORY STUDIES FOR THE APPROVAL OF NOVEL OR MODIFIED BLOOD PRODUCTS IN THE USA | $216,779 | Yes |
| 93.083 | PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES | $211,463 | Yes |
| 93.RD | TRANSFUSION-TRANSMISSIBLE INFECTIONS MONITORING SYSTEM (TTIMS) - DONATION DATABASE COORDINATING CENTER (DDCC) | $176,962 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $168,408 | Yes |
| 93.837 | CARDIOVASCULAR DISEASES RESEARCH | $147,983 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $90,434 | Yes |
| 93.866 | AGING RESEARCH | $79,784 | Yes |
| 47.084 | NSF TECHNOLOGY, INNOVATION, AND PARTNERSHIPS | $71,859 | Yes |
| 93.839 | BLOOD DISEASES AND RESOURCES RESEARCH | $45,210 | Yes |
| 93.847 | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH | $42,072 | Yes |
| 93.853 | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS | $32,416 | Yes |
What findings did the auditor report?
The reference and the requirement letter are the ones the auditor used. The finding text itself is not reproduced here; the FAC report linked above carries it in full.
The most recent report lists no finding.
Form 990 and IRS registration
Form 990 "accounting fees" (Part IX line 11c) cover all accounting services reported by the organization and are not the price of an audit engagement.
- Most recent return
- 990 for 2024-12
- Total revenue
- $739,592,382
- Total assets
- $891,045,288
- Accounting fees (Part IX line 11c)
- $637,696
- Paid preparer
- ERNST & YOUNG US LLP
- IRS object id
- 202522829349300142
- NTEE code
- E610
- Exempt under
- 501(c)(3)
- Ruling year
- 2015
- BMF release
- 2026-09-17
Read next
How we computed this
Every row comes from the Federal Audit Clearinghouse record named beside it, one report per audit year, with a resubmission superseding the filing it replaces. The auditor is the one named on that filing — it is not a statement about who audits Vitalant now. Form 990 figures come from the IRS e-filed return named by its object id. This page exists because the organization filed at least two single audits, or one with a finding.
Cite this page
AuditRadar. “Vitalant Single Audits and Findings (AZ).” https://getauditradar.com/single-audits/az/vitalant-860098929/. Data as of 2026-09-18.